Aethlon Medical, Inc. (NASDAQ: AEMD) shares move higher at Monday’s open, The company, a medical therapeutic concern focused on developing products to treat cancer and life-threatening infectious diseases, today announced that the Cancer Clinical Trial Unit at Royal Adelaide Hospital was activated on September 10, to begin screening and enrolling patients in its safety, feasibility and dose-finding clinical trial of the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The trial will be conducted by Prof. Michael Brown and his staff at the Cancer Clinical Trials Unit, CALHN, Royal Adelaide Hospital in Australia.
The activation follows the previously announced approval by the Human Research Ethics Committee at Central Adelaide Local Health Network on June 13, , and the Research Governance office at Royal Adelaide Hospital, on September 3, as well as the notification of the Therapeutic Good Administration (TGA) and completion of a Site Initiation Visit on September 9, 2024.
“The activation of the investigative site at the Royal Adelaide Hospital marks a significant milestone for Aethlon, allowing the site to screen and enroll patients in this important clinical trial,” stated Steven LaRosa, Chief Medical Officer of Aethlon Medical.
AEMD shares gathered a penny, or 2.9%, to 40 cents.
